OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on precision oncology. It designs small-molecule drugs that target specific cancer-driving mutations while sparing the normal version of the protein, an approach intended to improve tolerability.

The company's lead program, OKI-219, is a mutant-selective inhibitor of PI3K-alpha aimed at the H1047R mutation, which is common in breast cancer and other solid tumors. OnKure is studying the drug alone and in combination with standard breast cancer therapies, and it has additional programs targeting other PI3K-alpha mutations.

OnKure became a public company in 2024 through a merger with Reneo Pharmaceuticals, and its Class A common stock trades on the Nasdaq.